The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.

The present invention relates to a method of treating disorders caused by iron deficiency, comprising administering to a subject in need thereof a therapeutically effective amount of a formulation comprising, as active ingredients, a composition comprising at least 40% of 5′-ribonucleotides by weight of the total weight of the composition, and an inorganic iron salt.

The present invention relates to a method of treating disorders caused by iron deficiency, comprising administering to a subject in need thereof a therapeutically effective amount of a formulation comprising, as active ingredients, a composition comprising at least 40% of 5′-ribonucleotides by weight of the total weight of the composition, and an inorganic iron salt.

A composition comprising direct, indirect and related pathway endocannabinoid mimetic compounds and methods of using the composition.

The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction. ##STR00001##

A nutrition formulation, which is substantially free of at least one of valine and methionine and which is capable of parenteral or enteral administration. The nutrition formulation supplies sufficient nutrients to sustain life for at least three weeks by successive administration. A composition containing the nutrition formulation can be used for treating adult cell leukemia/lymphoma.

A nutrition formulation, which is substantially free of at least one of valine and methionine and which is capable of parenteral or enteral administration. The nutrition formulation supplies sufficient nutrients to sustain life for at least three weeks by successive administration. A composition containing the nutrition formulation can be used for treating adult cell leukemia/lymphoma.

The present invention addresses the problem of providing a novel composition which can make a contribution to athletic ability enhancement. The present invention provides an athletic ability enhancing composition including α-cyclodextrin as an active ingredient. The athletic ability enhancement includes at least one effect selected from among physical strength improvement, anti-fatigue, and fatigue feeling mitigation. In addition, the athletic ability enhancement also includes suppressing an increase in heart rate during exercise. Furthermore, provided is a composition which is for proliferating Bacteroides uniformis in the intestinal tract and includes α-cyclodextrin as an active ingredient. In the present invention, α-cyclodextrin is preferably administered in an amount of 0.01 mg/kg body weight to 200 mg/kg body weight per day, and preferably administered for at least seven days.

The present invention addresses the problem of providing a novel composition which can make a contribution to athletic ability enhancement. The present invention provides an athletic ability enhancing composition including α-cyclodextrin as an active ingredient. The athletic ability enhancement includes at least one effect selected from among physical strength improvement, anti-fatigue, and fatigue feeling mitigation. In addition, the athletic ability enhancement also includes suppressing an increase in heart rate during exercise. Furthermore, provided is a composition which is for proliferating Bacteroides uniformis in the intestinal tract and includes α-cyclodextrin as an active ingredient. In the present invention, α-cyclodextrin is preferably administered in an amount of 0.01 mg/kg body weight to 200 mg/kg body weight per day, and preferably administered for at least seven days.

Disclosed are preoperative compositions and methods of preparation thereof. The preoperative compositions may be for minimizing thirst, vomiting, insulin resistance, and the like prior to surgery. Such preoperative compositions may also reduce postoperative complications and the need for pain relievers, as well as minimize blood transfusion needed during and after surgery when administered the night before the operation and/or an hour before the operation. The preoperative compositions may include soymilk, isolate milk protein, isolate pea proteins, probiotics, whole milk powder, and micronutrients for example.